BLACR Bellevue Life Sciences Acquisition Corp. Rights

USD 0.14 0.00 0
Icon

Bellevue Life Sciences Acquisition Corp. Rights (BLACR) Stock Analysis and Price Targets

COMMON STOCK | | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.14

0.00 (0.00)%

N/A

1.65K

N/A

N/A

Icon

BLACR

Bellevue Life Sciences Acquisition Corp. Rights (USD)
COMMON STOCK | NSD
USD 0.14
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

N/A

N/A

USD 0.14

Bellevue Life Sciences Acquisition Corp. Rights (BLACR) Stock Forecast

N/A

Based on the Bellevue Life Sciences Acquisition Corp. Rights stock forecast from 0 analysts, the average analyst target price for Bellevue Life Sciences Acquisition Corp. Rights is not available over the next 12 months. Bellevue Life Sciences Acquisition Corp. Rights’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Bellevue Life Sciences Acquisition Corp. Rights is Neutral, which is based on 0 positive signals and 0 negative signals. At the last closing, Bellevue Life Sciences Acquisition Corp. Rights’s stock price was USD 0.14. Bellevue Life Sciences Acquisition Corp. Rights’s stock price has changed by +3.55% over the past week, -6.60% over the past month and -9.68% over the last year.

No recent analyst target price found for Bellevue Life Sciences Acquisition Corp. Rights
No recent average analyst rating found for Bellevue Life Sciences Acquisition Corp. Rights

Company Overview Bellevue Life Sciences Acquisition Corp. Rights

Bellevue Life Sciences Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. It intends to acquire companies in the healthcare ...Read More

N/A

N/A

0

N/A

USD

USA

Adjusted Closing Price for Bellevue Life Sciences Acquisition Corp. Rights (BLACR)

Loading...

Unadjusted Closing Price for Bellevue Life Sciences Acquisition Corp. Rights (BLACR)

Loading...

Share Trading Volume for Bellevue Life Sciences Acquisition Corp. Rights Shares

Loading...

Compare Performance of Bellevue Life Sciences Acquisition Corp. Rights Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for BLACR

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Bellevue Life Sciences Acquisition Corp. Rights (Sector: )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ATCOL
Atlas Corp 0.00 (0.00%) USD3.36B 14.10 N/A

ETFs Containing BLACR

Symbol Name BLACR's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Bellevue Life Sciences Acquisition Corp. Rights (BLACR) Stock

Stock Target Advisor's fundamental analysis for Bellevue Life Sciences Acquisition Corp. Rights's stock is Neutral.

Unfortunately we do not have enough data on BLACR's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on BLACR's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on BLACR's stock to indicate if its overvalued.

The last closing price of BLACR's stock was USD 0.14.

Unfortunately we do not currently have any market capitalization data for BLACR's stock.

Unfortunately we do not have enough analyst data on BLACR's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Bellevue Life Sciences Acquisition Corp. Rights's stock.

As per our most recent records Bellevue Life Sciences Acquisition Corp. Rights has 0 Employees.

Sorry we do not have any infomation available on Bellevue Life Sciences Acquisition Corp. Rights's address.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...